STOCKHOLM, Sweden--(BUSINESS WIRE)--The multi-center study in Sweden and Norway with ChronSeal® is now finalized and the data are being analyzed in Sweden and by Kringle in Japan. ChronTech and Kringle have jointly decided that the results will be publicly available on May 27th. At follow-up of the ChronVac-C® -study where patients now have started treatment according to standard-of-care (interferon and ribavirin) all patients (100%) were virus free at treatment week 12 and 5/6 (83%) had less than 50 copies of virus/mL blood already at treatment week four. This type of rapid treatment response is very unusual for patients infected with the hard to treat form of HCV called genotype 1 and further underscores a role for ChronVac-C® in a combination therapy.
